Perseus Proteomics Inc. (4882.T)
- Previous Close
430.00 - Open
425.00 - Bid 431.00 x --
- Ask 432.00 x --
- Day's Range
421.00 - 441.00 - 52 Week Range
298.00 - 1,113.00 - Volume
547,400 - Avg. Volume
1,437,615 - Market Cap (intraday)
6.353B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-75.72 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
www.ppmx.com25
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: 4882.T
View MorePerformance Overview: 4882.T
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4882.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4882.T
View MoreValuation Measures
Market Cap
6.34B
Enterprise Value
4.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
58.23
Price/Book (mrq)
3.45
Enterprise Value/Revenue
39.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.52%
Return on Equity (ttm)
-56.29%
Revenue (ttm)
111.39M
Net Income Avi to Common (ttm)
-898.75M
Diluted EPS (ttm)
-75.72
Balance Sheet and Cash Flow
Total Cash (mrq)
1.88B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--